{"schema_version":"secwatch.filing_event.v1","accession":"0001860742-24-000016","form_type":"8-K","ticker":"BLCO","cik":"0001860742","company_name":"Bausch & Lomb Corp","filed_at":"2024-10-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.141710+00:00","generated_at":"2026-05-30T08:32:51.473461+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Bausch + Lomb Q3 revenue $1.196B (+19% YoY); raises FY2024 revenue guidance","bullets":["GAAP net income $4M vs net loss of $84M YoY; adjusted EPS $0.13 ($0.17 ex-IPR&D).","Adjusted EBITDA $212M ($227M ex-IPR&D) vs $187M YoY, driven by broad-based sales growth.","Pharmaceuticals revenue surged 76% to $306M on XIIDRA acquisition and MIEBO launch.","FY2024 revenue guidance raised to $4.725-4.825B (prior $4.70-4.80B); adjusted EBITDA outlook unchanged.","Cash flow from operations $154M, up from $48M YoY, aided by gross profit and working capital."],"urls":{"canonical":"https://secwatch.observer/filing/0001860742-24-000016","json":"https://secwatch.observer/filing/0001860742-24-000016.json","markdown":"https://secwatch.observer/filing/0001860742-24-000016.md","text":"https://secwatch.observer/filing/0001860742-24-000016.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1860742/000186074224000016/0001860742-24-000016-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1860742/000186074224000016/blco-20241030.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T08:32:51.473461+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}